Provention Bio Announces Initiation of Phase 2b PROACTIVE Study of PRV-015 (anti-IL-15) in Non-responsive Celiac Disease
- Monday, August 31, 2020, 6:44
- Environment
- Add a comment
OLDWICK, N.J., Aug. 31, 2020 /PRNewswire/ — Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced the initiation of the Phase 2b PROACTIVE (PROvention Amgen Celiac ProtecTIVE) study of PRV-015,…
About the Author
adminasapcorp has written 41258 stories on this site.